Harrow (Nasdaq:HROW) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

HROW 주식 개요

는 안과용 의약품의 발견, 개발 및 상용화에 관여하는 안과용 제약 회사입니다.

HROW 기본 분석
눈송이 점수
가치 평가	5/6
미래 성장	5/6
과거 실적	0/6
재무 상태	2/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 84.8% 에서 거래

수익은 매년 73.61% 증가할 것으로 예상됩니다.

분석가들은 주가가 59.5% 상승할 것이라는 데 동의합니다.

위험 분석

최근 3개월간 주가 변동성

지난 1년 동안 주주가 희석되었습니다.

Harrow, Inc. 경쟁사

Liquidia

NasdaqCM:LQDA

US$941.0m

Evolus

NasdaqGM:EOLS

US$672.4m

Amryt Pharma

NasdaqGS:AMYT

US$940.7m

Collegium Pharmaceutical

NasdaqGS:COLL

US$1.0b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Harrow
과거 주가
현재 주가	US$21.00
52주 최고치	US$22.63
52주 최저치	US$7.60
베타	0.88
11개월 변경	13.15%
3개월 변경 사항	58.73%
1년 변경 사항	17.25%
33년 변화	131.02%
5년 변화	170.62%
IPO 이후 변화	142.81%

최근 뉴스 및 업데이트

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom

May 02

Recent updates

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

Sep 27

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Aug 19

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Aug 11

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

May 23

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

May 12

Is Harrow Health (NASDAQ:HROW) A Risky Investment?

Dec 15

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?

Aug 24

Harrow Health prices 8.625% senior notes due 2026

Jun 15

Harrow Health: An 8.3% Baby Bond Yield With Low Balance Sheet Leverage

May 28

Shareholders Shouldn’t Be Too Comfortable With Harrow Health's (NASDAQ:HROW) Strong Earnings

May 18

주주 수익률

	HROW	US Pharmaceuticals	US 마켓
7D	5.4%	1.2%	-0.2%
1Y	17.3%	20.0%	22.9%

수익률 대 산업: HROW 지난 1년 동안 20 %를 반환한 US Pharmaceuticals 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: HROW 지난 1년 동안 22.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is HROW's price volatile compared to industry and market?
HROW volatility
HROW Average Weekly Movement	12.7%
Pharmaceuticals Industry Average Movement	9.6%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

안정적인 주가: HROW 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: HROW 의 주간 변동성( 13% )은 지난 1년 동안 안정적이었지만 여전히 US 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
1998	315	Mark Baum	www.harrow.com

안과 전문 제약 회사인 Harrow는 안과용 의약품의 발견, 개발 및 상용화에 종사하고 있습니다. 이 회사는 안과 전문 복합 의약품인 ImprimisRx를 제공합니다. 또한 클로로프로카인 염산염 점안액인 이희조, 이오피딘, 베비, 제로비테 등의 점안액, 맥시트롤 점안액, 백내장 수술과 관련된 통증 및 염증을 위한 비스테로이드성 항염증 안약인 일레브로 및 네바낙, 세균성 결막염 치료를 위한 플루오로퀴놀론 항생제 점안액인 비가목스 등을 공급하고 있습니다; 안검 및 구결막, 각막, 안구 및 안구 전부의 스테로이드 반응성 염증 질환 치료제인 맥시덱스와 플라렉스, 안과 질환 치료 및 유리체 절제술 시 시야 확보를 위한 스테로이드 주사제 트리센스, 진균성 안검염, 결막염 및 각막염 치료를 위한 멸균 항진균제 나타신(NATACYN).

Harrow, Inc. 기본 사항 요약

Harrow 의 수익과 매출은 시가총액과 어떻게 비교하나요?
HROW 기본 통계
시가총액	US$755.05m
수익(TTM)	-US$31.33m
수익(TTM)	US$138.68m

5.4x

P/S 비율

-23.7x

P/E 비율

HROW 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
HROW 손익 계산서(TTM)
수익	US$138.68m
수익 비용	US$41.92m
총 이익	US$96.76m
기타 비용	US$128.09m
수익	-US$31.33m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-0.89
총 마진	69.77%
순이익 마진	-22.59%
부채/자본 비율	305.9%

HROW 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

HROW 주식 개요

보상

위험 분석

Harrow, Inc. 경쟁사

NasdaqCM:LQDA

US$941.0m

NasdaqGM:EOLS

US$672.4m

NasdaqGS:AMYT

US$940.7m

NasdaqGS:COLL

US$1.0b

가격 내역 및 성능

최근 뉴스 및 업데이트

Harrow Provides TRIESENCE Relaunch Update

Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study

Consensus EPS estimates fall by 68%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Harrow Names Greg Dipasquale as Senior Vice President, Head of Commercial

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom

Recent updates

Harrow Provides TRIESENCE Relaunch Update

Harrow, Inc. Announces 52-Week Data from VEVYE ESSENCE-2 Open-Label Extension Study

Consensus EPS estimates fall by 68%

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Harrow Names Greg Dipasquale as Senior Vice President, Head of Commercial

Harrow: The Bull Thesis Is On Track, But Short-Term Challenges Loom

Harrow, Inc., Annual General Meeting, Jun 14, 2024

Harrow, Inc. to Report Q1, 2024 Results on May 13, 2024

CEO & Chairman of the Board recently bought US$104k worth of stock

Forecast breakeven date pushed back to 2025

Full year 2023 earnings: EPS and revenues miss analyst expectations

Harrow, Inc. to Report Q4, 2023 Results on Mar 19, 2024

CEO & Chairman of the Board exercised options to buy US$1.1m worth of stock.

Harrow's Drug Iheezo Is Off To A Great Start

CEO & Chairman of the Board exercised options to buy US$166k worth of stock.

Harrow: Temporary Disruption In Stock Price Creates Excellent Opportunity

Harrow, Inc. Announces Board of Director Appointments

Harrow Announces Availability of Vevye® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease

Harrow, Inc. Completes Transfer of the TRIESENCE New Drug Application

CEO & Chairman of the Board recently bought US$61k worth of stock

New major risk - Financial position

Chief Commercial Officer exercised options and sold US$125k worth of stock

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Harrow, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Harrow, Inc. Completes Transfer of Ndas and Launches FLAREX, Natacyn St, Verkazia, and ZERVIATE in the U.S

Independent Director recently bought US$338k worth of stock

Forecast breakeven date pushed back to 2024

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Harrow Launches VIGAMOX in the U.S

CEO & Chairman of the Board exercised options and sold US$5.5m worth of stock

Harrow Health, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS misses analyst expectations

Forecast breakeven date pushed back to 2024

Harrow Announces to Launch FDA-Approved IHEEZO at 2023 American Society of Cataract and Refractive Surgery Annual Meeting

CEO & Chairman of the Board exercised options and sold US$1.4m worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Harrow Launches Next-Generation Compounded Atropine Formulations

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Funding LLC.

An unknown buyer acquired all shares in Harrow Health, Inc. from SWK Funding LLC.

Consensus forecasts updated

Harrow Health, Inc. Announces Availability of Fortisite Formulations for In-Office Use

CEO & Chairman of the Board exercised options and sold US$519k worth of stock

Chief of Formulation Strategy notifies of intention to sell stock

CEO & Chairman of the Board recently bought US$335k worth of stock

Harrow Health, Inc. has completed a Follow-on Equity Offering in the amount of $25.000002 million.

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Harrow Health, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Independent Director notifies of intention to sell stock

Harrow sells non‑ophthalmic compounding business, terms undisclosed

Harrow Health, Inc. and Sintetica, S.A. Announces U.S. FDA Approval of IHEEZO (Chloroprocaine Hydrochloride Ophthalmic Gel) 3% for Ocular Surface Anesthesia

Harrow Health soars ~27% on FDA nod of anesthesia gel for the surface of the eye

SRK Capital - Harrow Health: Market Missing The Forest For The Trees

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

These 4 Measures Indicate That Harrow Health (NASDAQ:HROW) Is Using Debt Extensively

Harrow Health, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Harrow Health, Inc. Launches IOPIDINE 1% and MAXITROL in the United States

Buy Deep Moated, Fast Growing, Superbly Managed Harrow Health Ahead Of New Product Launch

Consensus estimates of losses per share improve by 21%

Does Harrow Health (NASDAQ:HROW) Have A Healthy Balance Sheet?